Citadel Advisors’s scPharmaceuticals SCPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-38,900
Closed -$102K 14767
2025
Q1
$102K Buy
38,900
+400
+1% +$1.3K ﹤0.01% 11423
2024
Q4
$136K Buy
38,500
+18,000
+88% +$68.9K ﹤0.01% 11027
2024
Q3
$93.5K Sell
20,500
-6,800
-25% -$32.9K ﹤0.01% 11215
2024
Q2
$119K Sell
27,300
-9,000
-25% -$39.5K ﹤0.01% 10668
2024
Q1
$182K Sell
36,300
-10,000
-22% -$56K ﹤0.01% 10466
2023
Q4
$290K Buy
46,300
+8,400
+22% +$48.1K ﹤0.01% 9228
2023
Q3
$270K Sell
37,900
-20,100
-35% -$158K ﹤0.01% 9350
2023
Q2
$591K Buy
58,000
+35,600
+159% +$372K ﹤0.01% 7565
2023
Q1
$203K Buy
22,400
+13,800
+160% +$101K ﹤0.01% 10159
2022
Q4
$61.7K Sell
8,600
-4,800
-36% -$29.3K ﹤0.01% 11883
2022
Q3
$87K Buy
+13,400
New +$71.6K ﹤0.01% 11210

Citadel Advisors's SCPH Position: Q4 2025 in Review

Citadel Advisors sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 157,217 shares — an estimated $891K sold.

Citadel Advisors first reported a position in SCPH in Q2 2018 and held it in 16 quarters. The position peaked at $3.2M in Q2 2024. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

  • Citadel Advisors reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 157,217 scPharmaceuticals shares in Q4 2025, an estimated $891K.
  • Citadel Advisors first reported a position in scPharmaceuticals in Q2 2018 and held it in 16 quarters.
  • Citadel Advisors's scPharmaceuticals position peaked at $3.2M in Q2 2024.
  • 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.